Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...

Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif., Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical ...

Given that Ventura Securities has set a two-year target price of Rs 176, the broking firm thinks that the shares of NHPC ...

Ameluz-photodynamic therapy in superficial basal cell carcinoma may improve the clearance of target lesions, as shown in ...